OBJECTIVES: To identify drivers of time from diagnosis to treatment (TTT) of surgically resected early stage non-small cell lung cancer (NSCLC) and determine the effect of TTT on post-resection survival. SUMMARY BACKGROUND DATA: Large database studies that lack relevant comorbidity data have identified longer TTT as a driver of worse overall survival. METHODS: From 1/1/2014-4/1/2018, 599 patients underwent lung resection for clinical stage I and II NSCLC. Random forest classification, regression, and survival were used to estimate likelihood of TTT=0 (tissue diagnosis obtained at surgery), > 0 (diagnosis obtained pre-resection), and effect of TTT on all-cause mortality. RESULTS: Patients with TTT > 0 (n=413) had median TTT of 42 days [25-75th percentile: 27-59 days]. Patients with TTT=0 (n=186) had smaller tumors and higher percent predicted forced expiratory volume in one second (FEV1%). Patients with history of stroke, oncology consultation, invasive mediastinal staging, low and high extremes of FEV1% had longer TTT. Higher clinical stage, lack of preoperative stress test, anemia, older age, lower FEV1% and diffusion lung capacity, larger tumor size, and longer TTT were the most important predictors of all-cause mortality. One- and five-year overall survival decreased when TTT was longer than 50 days. CONCLUSION: Preoperative physiologic workup and multidisciplinary evaluation were the predominant drivers of longer TTT. Patients with TTT=0 have more favorable presentation and should be considered in TTT analyses for early stage lung cancer populations. The time needed to clinically stage and optimize patients for resection is not deleterious to overall survival until resection is performed after 50 days from diagnosis.
OBJECTIVES: To identify drivers of time from diagnosis to treatment (TTT) of surgically resected early stage non-small cell lung cancer (NSCLC) and determine the effect of TTT on post-resection survival. SUMMARY BACKGROUND DATA: Large database studies that lack relevant comorbidity data have identified longer TTT as a driver of worse overall survival. METHODS: From 1/1/2014-4/1/2018, 599 patients underwent lung resection for clinical stage I and II NSCLC. Random forest classification, regression, and survival were used to estimate likelihood of TTT=0 (tissue diagnosis obtained at surgery), > 0 (diagnosis obtained pre-resection), and effect of TTT on all-cause mortality. RESULTS: Patients with TTT > 0 (n=413) had median TTT of 42 days [25-75th percentile: 27-59 days]. Patients with TTT=0 (n=186) had smaller tumors and higher percent predicted forced expiratory volume in one second (FEV1%). Patients with history of stroke, oncology consultation, invasive mediastinal staging, low and high extremes of FEV1% had longer TTT. Higher clinical stage, lack of preoperative stress test, anemia, older age, lower FEV1% and diffusion lung capacity, larger tumor size, and longer TTT were the most important predictors of all-cause mortality. One- and five-year overall survival decreased when TTT was longer than 50 days. CONCLUSION: Preoperative physiologic workup and multidisciplinary evaluation were the predominant drivers of longer TTT. Patients with TTT=0 have more favorable presentation and should be considered in TTT analyses for early stage lung cancer populations. The time needed to clinically stage and optimize patients for resection is not deleterious to overall survival until resection is performed after 50 days from diagnosis.
Authors: Candice L Wilshire; Joshua R Rayburn; Shu-Ching Chang; Christopher R Gilbert; Brian E Louie; Ralph W Aye; Alexander S Farivar; Adam J Bograd; Eric Vallières; Jed A Gorden Journal: Ann Thorac Surg Date: 2020-05-31 Impact factor: 4.330
Authors: Chi-Fu Jeffrey Yang; Hanghang Wang; Arvind Kumar; Xiaofei Wang; Matthew G Hartwig; Thomas A D'Amico; Mark F Berry Journal: Chest Date: 2017-08-08 Impact factor: 9.410
Authors: Lee A Fleisher; Kirsten E Fleischmann; Andrew D Auerbach; Susan A Barnason; Joshua A Beckman; Biykem Bozkurt; Victor G Davila-Roman; Marie D Gerhard-Herman; Thomas A Holly; Garvan C Kane; Joseph E Marine; M Timothy Nelson; Crystal C Spencer; Annemarie Thompson; Henry H Ting; Barry F Uretsky; Duminda N Wijeysundera Journal: J Am Coll Cardiol Date: 2014-08-01 Impact factor: 24.094
Authors: Amelia W Maiga; Stephen A Deppen; Rhonda Pinkerman; Carol Callaway-Lane; Pierre P Massion; Robert S Dittus; Eric S Lambright; Jonathan C Nesbitt; David Baker; Eric L Grogan Journal: Ann Thorac Surg Date: 2017-10-21 Impact factor: 4.330
Authors: Daniel R Gomez; Kai-Ping Liao; Stephen G Swisher; George R Blumenschein; Jeremy J Erasmus; Thomas A Buchholz; Sharon H Giordano; Benjamin D Smith Journal: Radiother Oncol Date: 2015-05-23 Impact factor: 6.280
Authors: Mariëlle M M T J Ouwens; Rosella R P M G Hermens; René A R Termeer; Saskia Y Vonk-Okhuijsen; Vivianne C G Tjan-Heijnen; Ad F T M Verhagen; Marlies M E J L Hulscher; Henri A M Marres; Hub C H Wollersheim; Richard P T M Grol Journal: Cancer Date: 2007-10-15 Impact factor: 6.860
Authors: Margo M Jacobsen; Sophie C Silverstein; Michael Quinn; Leo B Waterston; Christian A Thomas; James C Benneyan; Paul K J Han Journal: Lung Cancer Date: 2017-08-15 Impact factor: 5.705
Authors: Alok A Khorana; Katherine Tullio; Paul Elson; Nathan A Pennell; Stephen R Grobmyer; Matthew F Kalady; Daniel Raymond; Jame Abraham; Eric A Klein; R Matthew Walsh; Emily E Monteleone; Wei Wei; Brian Hobbs; Brian J Bolwell Journal: PLoS One Date: 2019-03-01 Impact factor: 3.240
Authors: Matthew D Pichert; Maureen E Canavan; Richard C Maduka; Andrew X Li; Theresa Ermer; Peter L Zhan; Michael Kaminski; Brooks V Udelsman; Justin D Blasberg; Vincent J Mase; Andrew P Dhanasopon; Daniel J Boffa Journal: JTO Clin Res Rep Date: 2022-04-06